<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

1   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

2   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

 

Discover the infinite power of partnership to drive scientific discovery

Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.

We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.

Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.

Oncology Databases

Quickly Find Models to Fit Your Research Needs

Learn More

Latest News

Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank

Read More

Learn more about our services

Therapeutic Areas

Leverage our extensive experience in oncology, immuno-oncology, immune-mediated inflammatory and cystopathic diseases

Learn More

Model Systems

Discover the largest commercially available collection of PDX models as well as our novelin vitro models

Learn More

Technologies

Utilize our bioinformatics, biomarker analysis, genomics and high content imaging services to advance your preclinical studies

Learn More

Service Types

Accelerate your drug development with our biomarker discovery, efficacy testing, DMPK and pharmacology services

Learn More

Review our published work!

Crown Bioscience is an expert preclinical CRO.

Latest Resources

Latest Factsheet

Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services

Next Generation Ion Mobility Mass Spectrometry-based Proteomics Services

View Factsheet

Latest Application Note

HCC827 NSCLC Cell Line Derived Xenograft Model

Evaluate immunotherapeutics and agents to overcome drug resistance with our NSCLC EGFR exon 19 deletion resources

View Application Note

Latest Poster

3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing

3D Ex vivo Patient Tissue Platform for Immuno-Oncology Drug Testing

View Poster

Latest Webinar

Preclinical biomarker discovery via in vivo and in vitro screening

Preclinical biomarker discovery via in vivo and in vitro screening

View Webinar

Latest Blog Posts

January 11, 2023

Organoid Technology: A Reliable Tool for Drug Screening

It is well-known that drug attrition rates for anticancer agents are very high. In fact, only about 5% of compounds in preclinical development eventually becoming approved for clinical use. The need for more clinically relevant preclinical models has been identified as one of the areas that can reduce this attrition rate by enabling better decisions when selecting agents to advance to the clinic.

Read

December 15, 2022

Transforming Drug Discovery with 3D Adult Stem Cell Organoids and High Content Imaging

3D adult stem cell (ASC)-derived tumor organoids can enhance the translatability of drug discovery data, especially in combination with high content imaging (HCI). In this blog post, we explore how the pairing of these two technologies allows researchers to develop highly comprehensive and predictive data that can enable better decisions earlier in drug discovery, while improving the translatability of the most promising lead compounds.

Read

November 30, 2022

Applications of Genetically Engineered Organoids and Cell Lines

This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models. Several case studies are presented to showcase their application for target validation and in vitro /in vivo efficacy studies.

Read

November 10, 2022

How 3D In Vitro Organoids Can Enhance the Predictivity of Cancer Drug Discovery

Drug development is a lengthy, risky, and costly endeavor with high candidate attrition. Attrition rates for anticancer agents are much higher than in other therapeutic categories. Only 5% of them are estimated to reach the clinical stage. This very high rate has been attributed in part to the poor translatability of current preclinical data.

Read

Ensuring that every patient has the right
treatment at the right time.